Journal Information
Most cited
69
Clinical treatment of cholangiocarcinoma: an updated comprehensive reviewAlessandra Elvevi, Alice Laffusa, Miki Scaravaglio, Roberta Elisa Rossi, Raffaella Longarini, Anna Maria Stagno, Laura Cristoferi, Antonio Ciaccio, ... Sara Massironi
Ann Hepatol. 2022;27:100737
69
Open access
44
From Child-Pugh to MELD score and beyond: Taking a walk down memory laneAndres Ruf, Melisa Dirchwolf, Richard B. Freeman
Ann Hepatol. 2022;27:100535
44
Open access
41
Causes of death in patients with Non-alcoholic Fatty Liver Disease (NAFLD), alcoholic liver disease and chronic viral Hepatitis B and CPegah Golabi, James M. Paik, Katherine Eberly, Leyla de Avila, Saleh A. Alqahtani, Zobair M. Younossi
Ann Hepatol. 2022;27:100556
41
Open access
32
The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based studyOsama Hamid, Ahmed Eltelbany, Abdul Mohammed, Khaled Alsabbagh Alchirazi, Sushrut Trakroo, Imad Asaad
Ann Hepatol. 2022;27:100727
32
Open access
25
Non-alcoholic fatty liver disease prevalence in Latin America: A systematic review and meta-analysisYesmi A. Ortega Rojas, Claudia L. Vidal Cuellar, Karina M. Aparicio Barrón, Juan Pablo Arab, Adelina Lozano Miranda
Ann Hepatol. 2022;27:100706
25
Full text access
24
Silencing lncRNA NEAT1 reduces nonalcoholic fatty liver fat deposition by regulating the miR-139-5p/c-Jun/SREBP-1c pathwaySi-Si Jin, Chun-Jing Lin, Xian-Fan Lin, Ju-Zeng Zheng, Hua-Qin Guan
Ann Hepatol. 2022;27:100584
24
Open access
22
NAFLD VS MAFLD. The evidence-based debate has come. Time to change?Diego García-Compeán, Alan Rafael Jiménez-Rodríguez
Ann Hepatol. 2022;27:100765
22
Full text access
22
Caffeine mitigates experimental nonalcoholic steatohepatitis and the progression of thioacetamide-induced liver fibrosis by blocking the MAPK and TGF-β/Smad3 signaling pathwaysEduardo E. Vargas-Pozada, Erika Ramos-Tovar, Consuelo Acero-Hernández, Irina Cardoso-Lezama, Silvia Galindo-Gómez, Víctor Tsutsumi, Pablo Muriel
Ann Hepatol. 2022;27:100671
22
Open access
21
miR-221-3p regulates hepatocellular carcinoma cell proliferation, migration and invasion via targeting LIFRWei Tan, Zhuokai Li, Weifen Xia, Jinde Zhu, Rengen Fan
Ann Hepatol. 2022;27 Supl 1:100567
21
Open access
19
Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidenceCiro Celsa, Caterina Stornello, Paolo Giuffrida, Carmelo Marco Giacchetto, Mauro Grova, Gabriele Rancatore, Concetta Pitrone, Vito Di Marco, ... Giuseppe Cabibbo
Ann Hepatol. 2022;27 Supl 1:100568
19
Open access